Immortalized and tumorigenic adult human prostatic epithelial cell lines: Characteristics and applications. Part 3. Oncogenes, suppressor genes, and applications

Prostate

Volumn 30, Issue 2, 1997, Pages 136-142

  Webber, Mukta M ^a   Bello, Diana ^a   Quader, Salmaan ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

cell lines; chemoprevention and intervention; chemotherapeutic drugs; drug resistance; hormonal control; invasion and metastasis; prostate cancer; prostate specific antigen; ras oncogene; suppressor genes

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BLOOD CLOTTING FACTOR 8; CYTOKERATIN; DESMIN; GROWTH FACTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

CANCER CELL CULTURE; CARCINOGENESIS; GENE MUTATION; HUMAN; HUMAN CELL; MALE; MALIGNANT TRANSFORMATION; METASTASIS; ONCOGENE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; REVIEW; SIMIAN VIRUS 40; TUMOR SUPPRESSOR GENE; WART VIRUS;

EPITHELIAL CELLS; GENES, P53; GENES, RAS; HUMANS; MALE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0031028190     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970201)30:2<136::AID-PROS9>3.0.CO;2-M     Document Type: Review

References (70)

1. Webber MM, Bello D, Quader S: Immortalized and tumorigenic adult human prostatic epithelial cell lines: Characteristics and applications. Part 1. Cell markers and immortalized non-tumorigenic cell lines. Prostate 29:386-394, 1996.
2. Webber MM, Bello D, Quader S: Immortalized and tumorigenic adult human prostatic epithelial cell lines: Characteristics and applications. Part 2. Tumorigenic cell lines. Prostate 30:58-64, 1997.
3. Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzuka M: Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res 52:5991-5996, 1992.
4. Konishi N, Enomoto T, Buzard G, Ohshima M, Ward JM, Rice JM: K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer 69: 2293-2299, 1992.
5. Sumiya H, Masai M, Akimoto S, Yatani R, Shimazaki J: Histochemical examination of expression of ras p21 protein and R 1881-binding protein in human prostatic cancers. Eur J Cancer 26:786-789, 1990.
6. Carter BS, Epstein JI, Isaacs WB: ras gene mutations in human prostate cancer. Cancer Res 50:6830-6832, 1990.
7. Konishi N, Hiasa Y, Matsuda H, Ming T, Kitahori Y: Intratumoral cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Proc Am Assoc Cancer Res 36:143, 1995.
8. Bello D, Webber MM, Kleinman HK, Warringer DD, Rhim JS: Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18 (submitted), 1997.
9. Rhim JS, Webber MM, Bello D, Lee MS, Arnstein P, Chen L, Jay G: Stepwise immortalization and transformation of adult human prostate epithelial cells by a combination of HPV-18 and v-Ki-ras. Proc Natl Acad Sci USA 91:11874-11878, 1994.
10. Gumerlock PH, Poonamallee UR, Meyers FJ, White RW: Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res 51:1632-1637, 1991.
11. Yamazaki H, Schneider E, Myers CE, Sinha BK: Oncogene expression and de novo drug-resistance in human prostate cancer cells. Biochim Biophys Acta 1226:89-96, 1994.
12. Rijnders AWM, van der Korput JAGM, van Steenbrugge, Romijn JC, Trapman J: Expression of cellular oncogenes in human prostatic carcinoma cell lines. Biochem Biophys Res Commun 132:548-554, 1985.
13. Singh J, Kelloff G, Reddy BS: Intermediate biomarkers of colon cancer: Modulation of expression of ras oncogene by chemopreventive agents during azoxymethane induced colon carcinogenesis. Carcinogenesis 14:699-704, 1993.
14. Borden EC, Lotan R, Levens D, Young CW: Differentiation therapy of cancer: Laboratory and clinical investigations (meeting report). Cancer Res 53:4109-4115, 1993.
15. Webber MM, Bello D, Kleinman HK, Warringer DD, Williams DE, Rhim JS: Prostate specific antigen and androgen receptor induction and characterization of an immortalized adult human prostatic epithelial cell line. Carcinogenesis 17:1641-1646, 1996.
16. Furihata M, Inoue K, Ohtsuki Y, Hashimoto H, Terao N, Fujita Y: High risk papillomavirus infections and overexpression of p53 protein as prognostic indicator in transitional cell carcinoma of the urinary bladder. Cancer Res 53:4823-4827, 1993.
17. Chi SG, White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH: p53 in prostate cancer: Frequent expressed transition mutations. J Natl Cancer Inst 86:926-933, 1994.
18. Kubota Y, Shuin H, Fujinami K, Miyamoto H, Torigoe S, Dobashi Y, Kitamura H, Iwasaki Y, Danenberg K, Danenberg V: Tumor suppressor gene p53 mutations in human prostate cancer. Prostate 27:18-24, 1995.
19. Yang G, Stapleton AMF, Wheeler TM, Truong LD, Timme TL, Scardino PT, Thompson TC: Clustered p53 immunostaining: A novel pattern associated with prostate cancer progression. Clin Cancer Res 2:399-401, 1996.
20. Bauer JJ, Sesterhenn IA, Mostofi KF, McLeod DG, Srivastava S, Moul JW: p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. CHn Cancer Res 1:1295-1300, 1995.
21. Eastham JA, Stapleton AMF, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT, Thompson TC: Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1:1111-1118, 1995.
22. Carroll AG, Voeller JH, Sugars L, Gelmann EP: p53 oncogene mutation in three human prostate cancer cells lines. Prostate 23:123-134, 1993.
23. Isaacs WB, Carter BS, Ewing CM: Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51:4716-4720, 1991.
24. Bookstein R, Shew J, Chen P, Scully P, Lee W: Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712-715, 1990.
25. Carruba G, Pfeffer U, Fecarotta E, Coviello DA, D'Amato E, Casto ML, Vidali G, Castagnetta L: Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cancer cells. Cancer Res 54:1190-1193, 1994.
26. Dawson NA, Kobayashi K, Vogelzang NJ: Recent therapeutic advances in "Hormone-Refractory" metastatic prostate cancer: flutamide withdrawal, estramustine plus vinblastine, estramustine plus etoposide, and suramin. In Dawson NA, Vogelzang NJ (eds): "Prostate Cancer." New York: Wiley-Liss, 1994, pp 235-260.
27. Hartley-Asp B: Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3. Prostate 5:93-100, 1984.
28. Pienta KJ, Lehr JE: Inhibition of prostate cancer growth by estramustine and etoposide: Evidence for interaction at the nuclear matrix. J Urol 149:1622-1625, 1993.
29. Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E, Motta M: Antiproliferative effects of lutenizing hormone-releasing hormone (LRHR) agonists on human androgen-independent prostate cancer cell line DU-145: Evidence for an autocrine-inhibitory LHRH loop. Cancer Res 54:4091-4095, 1994.
30. Metcalfe SA, Whelan RDH, Masters JRW, Hill BT: In vitro responses of human prostate tumour cell lines to a range of antitumour agents. Int J Cancer 32:351-358, 1983.
31. Kaver I, Ware JL, Wilson JD, Koontz WW: Effect of radiation combined with hyperthermia on human prostatic carcinoma cell lines in culture. Urology 38:88-92, 1991.
32. Sica G, Fabbroni L, Castagnetta L, Cacciatore M, Pavone-Macaluso M: Antiproliferative effect of interferons on human prostate carcinoma cell lines. Urol Res 17:111-115, 1989.
33. Goldstein D, O'Leary M, Mitchen J, Borden EC, Wilding G: Effects of Interferon βSER and transforming growth factor β on prostatic cell lines. J Urol 146:1173-1177, 1991.
34. Röyttä M, Laine K-M, Härkönen P: Morphological studies on the effect of taxol on cultured human prostatic cancer cells. Prostate 11:95-106, 1987.
35. Stearns ME, Wang M: Taxol blocks processes essential fro prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res 52:3776-3781, 1992.
36. Qiao L, Pizzolo JG, Melamed MR: Effects of suramin on expression of proliferation associated nuclear antigens in DU-145 prostate carcinoma cells. Biochem Biophys Res Commun 201:581-588, 1994.
37. Berns EMJJ, Schuurmans LG, Bolt J, Lamb DJ, Foekens JA, Mulder E: Antiproliferative effects of suramin on androgen responsive cells. Eur J Cancer 26:470-474, 1990.
38. Ewing MW, Liu SC, Gnarra JR, Walther MM, Meyers CE, Linehan WM: Effect of suramin on the mitogenic response of the human prostate carcinoma cell line PC-3. Cancer 71:1151-1158, 1993.
39. Fruehauf JP, Myers CE, Sinha BK: Synergistic activity of suramin with tumor necrosis factor a and doxorubicin on human prostate cancer cell lines. J Natl Cancer Inst 82:1206-1209, 1990.
40. Webber MM, Rehman SMM, James JT: Metallothionein induction and deinduction in human prostatic carcinoma cells: Relationship with resistance and sensitivity to adriamycin. Cancer Res 48:4503-4508, 1988.
41. Theyer G, Schirmböck M, Thalhammer T, Sherwood ER, Baumgartner G, Hamilton G: Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. J Urol 150:1544-1547, 1993.
42. Metcalfe SA, Cain K, Hill BT: Possible mechanisms for differences in sensitivity to cis-platinum in human prostate tumor cell lines. Cancer Lett 31:163-169, 1986.
43. Ripple M, Mulcahy RT, Wilding G: Characteristics of the glutathione/glutathione-s-transferase detoxification system in melphalan resistant human prostate cancer cells. J Urol 150:209-214, 1993.
44. Waghray A, Webber MM: Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells. Clin Cancer Res 1:747-753, 1995.
45. Webber MM, Waghray A: Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid. Clin Cancer Res 1:755-761, 1995.
46. Webber MM, Waghray A, Bello D: Prostate specific antigen (PSA), a serine protease, facilitates human prostate cancer invasion. CHn Cancer Res 1:1089-1094, 1995.
47. Webber MM, Waghray A, Bello D, Rhim JS: Proteases and invasion in human prostate epithelial cell lines: Implications in prostate cancer prevention and intervention. Radiat Oncol Invest 3:358-362, 1996.
48. Hoosein NM, Boyd DD, Hollas WJ, Mazar A, Henkin J, Chung LWK: Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun 3:255-264, 1991.
49. Jarrard DF, Blitz BF, Smith RC, Patai BL, Rukstalis DB: Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion. Prostate 24:46-53, 1994.
50. Yoshida E, Verrusio E, Mihara H, Oh D, Kwaan H: Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. Cancer Res 54:3300-3304, 1994.
51. Passaniti A, Isaacs JT, Haney JA, Adler SW, Cujdik TJ, Long PV, Kleinman HK: Stimulation of human prostatic carcinoma tumor growth in athymic mice and control of migration in culture by extracellular matrix. Int J Cancer 51:318-324, 1992.
52. Thalmann GN, Anezinis PE, Chang S, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LWK: Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54:2577-2581, 1994.
53. Witkowski CM, Rabinovitz I, Nagle RB, Affinito KD, Cress AE: Characterization of integrin subunits, cellular adhesion and tumorigenicity of four human prostate cancer cell lines. J Cancer Res Clin Oncol 119:637-644, 1993.
54. Linehan MR: Inhibition of prostate cancer metastasis: a critical challenge ahead. J Natl Cancer Inst 87:331-332, 1995.
55. Reichman ME, Hayes RB, Ziegler RG, Schatzkin A, Taylor PR, Kahle LL, Fraumeni JR Jr: Serum vitamin A and subsequent development of prostate cancer in the first national health and nutrition examination survey epidemiologic follow-up study. Cancer Res 50:2311-2315, 1990.
56. Dahiya DB, Park HD, Cusick J, Vessella RL, Fournier G, Narayan P: Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int J Cancer 59:126-132, 1994.
57. Igawa M, Tanabe T, Chodak GW, Rukstalis DB: N-(4-hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC3 cells. Prostate 24:299-305, 1994.
58. Bello D, Metcalfe WS, Waghray A, Webber MM: Vimentin expression and invasive ability of DU-145 human prostate carcinoma cells is modulated by N-(4-hydroxyphenyl) retinamide (4-HPR). Clin Exp Metastasis 12:57, 1994.
59. Ip C, Ganther HE: Relationship between the chemical form of selenium and anticarcinogenic activity. In Wattenberg L, Lipkin M, Boone CW (eds): "Cancer Chemoprevention." Boca Raton, FL: CRC Press, 1992, pp 479-488.
60. Webber MM, Perez-Ripoll EA, James GT: Inhibitory effects of selenium on the growth of DU-145 human prostate carcinoma cells in vitro. Biochem Biophys Res Comm 130:603-609, 1985.
61. Willett WC, Hunter D: Vitamin A and cancers of the breast, large bowel, and prostate: Epidemiological evidence. Nutri Rev 52:S53-S59, 1994.
62. Grandis JR, Zeng Q, Tweardy DJ: Retinoic acid normalizes the increased gene transcription rate of TGF-α and EGFR in head and neck cell lines. Nature Med 2:237-240, 1996.
63. Kazmi SMI, Plante RK, Visconti V, Lau CY: Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid-receptor-mediated expression in human breast cancer cell lines. Cancer Res 56:1056-1062, 1996.
64. Takahashi N, Sausville EA, Breitman TR: N-(4-hydroxyphenyl)retinamide (Fenretinide) in combination with retinoic acid enhances differentiation and retinylation of proteins. CHn Cancer Res 1:637-642, 1995.
65. Smets G, Van Ginckel R, Daneels G, Moeremans M, Van Wauwe J, Coens MC, Ramaekers FCS, Schalken JA, Borgers M, De Coster R: Liarozole, an antitumor drug, modulates cytokeratin expression in the Dunning AT-6sq prostatic carcinoma through in situ accumulation of ati-trans retinoic acid. Prostate 27:129-140, 1995.
66. Takatsuka J, Takahashi N, De Luca LM: Retinoic acid metabolism and inhibition of cell proliferation: An unexpected liaison. Cancer Res 56:675-678, 1996.
67. Lotan R: Retinoids and apoptosis: Implications for cancer chemoprevention and therapy. J Natl Cancer Inst 87:1655-1657, 1995.
68. Scalmati A, Lipkin M, Newmark H: Relationships of calcium and vitamin D to colon cancer. In Wattenberg L, Lipkin M, Boone CW (eds): "Cancer Chemoprevention." Boca Raton, FL: CRC Press, 1992, pp 249-262.
69. 3. Cancer Res 52: 515-520, 1992.
70. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952-1960, 1993.